Original Article

Effects of Tocilizumab Therapy on Serum Interleukin-33 and Interleukin-6 Levels in Patients With Rheumatoid Arthritis

Volume 33 · Issue 4 Publish Date: December 31, 2018
Full Text PDF HTML
DOI
In Ah CHOI
Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, South Korea image/svg+xml
Eun Bong LEE
Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea image/svg+xml
Eun Young LEE
Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea image/svg+xml
Hoon-Suk CHA
Department of Internal Medicine, Sam Sung Medical Center, Seoul, Seoul, South Korea image/svg+xml
Young Eun PARK
Department of Internal Medicine, Pusan National University Hospital, Busan, South Korea image/svg+xml
Yun Jong LEE
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea image/svg+xml
Soo Kon LEE
Department of Internal Medicine, CHA Bundang Medical Center, Seongnam, South Korea image/svg+xml
Hyun Ah KIM
Department of Internal Medicine, Hallym University Medical Center, Anyang, South Korea image/svg+xml
Dae-Hyun YOO
Department of Internal Medicine, Hanyang University Medical Center, Seoul, South Korea image/svg+xml
Han Joo BAEK
Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea image/svg+xml
Seung-cheol SHIM
Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea image/svg+xml
Sung Hwan PARK
Department of Internal Medicine, The Catholic University of Korea Seoul St. Mary’s Hospital, Seoul, South Korea image/svg+xml
Won PARK
Department of Internal Medicine, Inha University Hospital, Incheon, South Korea image/svg+xml
Sang Jin LEE
Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Medical Research Institute, Seoul National University, Seoul, South Korea image/svg+xml
Yeong Wook SONG
Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Medical Research Institute, Seoul National University, Seoul, South Korea image/svg+xml
In Ah CHOI, Eun Bong LEE, Eun Young LEE, Hoon-Suk CHA, Young Eun PARK, Yun Jong LEE, … Yeong Wook SONG. (2018). Effects of Tocilizumab Therapy on Serum Interleukin-33 and Interleukin-6 Levels in Patients With Rheumatoid Arthritis. Archives of Rheumatology, 33(4), 389–394. https://doi.org/10.5606/ArchRheumatol.2018.6753
Full Text PDF HTML

Abstract

Objectives: This study aims to examine the effects of tocilizumab therapy on serum levels of interleukin (IL)-33 and IL-6 in rheumatoid arthritis (RA) patients.

Patients and methods: Interleukin-33 and IL-6 levels in serum samples from 83 RA patients (10 males, 73 females; mean age 51.9 years; range, 26 to 77 years) and 12 healthy controls (2 males, 10 females; mean age 52.2 years; range, 39 to 62 years) were compared by cross-sectional, case control analysis. Of the RA patients, 40 received 24 weeks of tocilizumab therapy and were assigned to the prospective cohort. These 40 patients were then divided into two subgroups as responders and non-responders according to the American College of Rheumatology (ACR) 20. The remaining 43 RA patients did not receive tocilizumab therapy. Serum cytokine levels were analyzed at baseline and after 24 weeks of tocilizumab therapy in these patients.

Results: Interleukin-33 and IL-6 concentrations were significantly higher in RA patients than in healthy controls (p<0.001 for both). Serum IL-33 levels in RA patients showed a significant correlation with rheumatoid factor titer (r=0.660, p<0.001), and IL-6 levels showed a significant correlation with high-sensitivity C-reactive protein levels (Spearman's rank correlation coefficient=0.482, p<0.001). Serum IL-33 levels decreased significantly after 24 weeks of tocilizumab therapy (p<0.001); this was particularly marked in ACR20 responders (p<0.001). However, the decrease in non-responders was not significant (p=0.066). Changes in serum IL-6 levels after 24 weeks of tocilizumab therapy were not significant in either ACR20 responders or non-responders.

Conclusion: Serum IL-33 levels in RA patients receiving tocilizumab therapy decreased significantly, particularly in ACR20 responders. Thus, IL-33 may be a useful marker for monitoring responses to tocilizumab therapy.

Similar Articles

Article Info
Published In
Journal Archives of Rheumatology
Volume / Issue Volume 33 · Issue 4
Pages 389-394
History
Published Online December 31, 2018
License
Affiliations
In Ah CHOI
Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, South Korea
Eun Bong LEE
Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Eun Young LEE
Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Hoon-Suk CHA
Department of Internal Medicine, Sam Sung Medical Center, Seoul, Seoul, South Korea
Young Eun PARK
Department of Internal Medicine, Pusan National University Hospital, Busan, South Korea
Yun Jong LEE
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
Soo Kon LEE
Department of Internal Medicine, CHA Bundang Medical Center, Seongnam, South Korea
Hyun Ah KIM
Department of Internal Medicine, Hallym University Medical Center, Anyang, South Korea
Dae-Hyun YOO
Department of Internal Medicine, Hanyang University Medical Center, Seoul, South Korea
Han Joo BAEK
Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea
Seung-cheol SHIM
Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea
Sung Hwan PARK
Department of Internal Medicine, The Catholic University of Korea Seoul St. Mary’s Hospital, Seoul, South Korea
Won PARK
Department of Internal Medicine, Inha University Hospital, Incheon, South Korea
Sang Jin LEE
Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Medical Research Institute, Seoul National University, Seoul, South Korea
Yeong Wook SONG
Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Medical Research Institute, Seoul National University, Seoul, South Korea
Cite this Article
In Ah CHOI, Eun Bong LEE, Eun Young LEE, Hoon-Suk CHA, Young Eun PARK, Yun Jong LEE, … Yeong Wook SONG. (2018). Effects of Tocilizumab Therapy on Serum Interleukin-33 and Interleukin-6 Levels in Patients With Rheumatoid Arthritis. Archives of Rheumatology, 33(4), 389–394. https://doi.org/10.5606/ArchRheumatol.2018.6753
Share
Outlines